Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil in Young HIV-Positive MSM
NCT01209325Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Jun 2011
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of qHPV vaccine in human papillomavirus infection, condyloma acuminatum, anal intraepithelial neoplasia (AIN) and 2 more, sponsored by AIDS Malignancy Consortium. Primary endpoints: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6, 11, 16, 18 DNA, Incidence of Persistent Anogenital Infection With HPV 6, 11, 16, 18 DNA and 2 more. Started Jun 2011; status: completed.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectioncondyloma acuminatumanal intraepithelial neoplasia (AIN)anal cancerpenile cancer
Beyond the preview
Go deeper on NCT01209325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01209325.